A recent SELECT trial analysis demonstrates that the 20% drop in major heart events among semaglutide users cannot be entirely explained by patients shedding pounds. While standard medical advice often emphasizes healthy weight reduction to protect the heart, researchers discovered that only half of the drug’s benefits are tied to changes in weight, waist circumference, or blood pressure. This finding fundamentally changes how experts view semaglutide cardiovascular disease prevention, positioning the medication as a direct cardiovascular treatment rather than just an obesity drug.
Unexplained Cardiovascular Protection
Led by Professor Helen Colhoun from the University of Edinburgh, the research team examined data from 17,604 overweight or obese patients over a two-year period. They tracked changes in cholesterol, blood sugar, inflammation markers, and kidney function alongside physical measurements. Even when combining all these conventional risk factors, the calculations did not fully account for the substantial decrease in heart attacks and strokes observed in the group receiving the GLP-1 receptor agonist.
The Search for Mechanisms
While the exact physiological pathways remain unconfirmed, experts suspect the medication may exert direct, protective effects on the heart muscle or blood vessel linings. The drug might also trigger anti-inflammatory responses that standard clinical tests fail to capture. As scientists continue to search for the precise biological underpinnings, the medical community is encouraged to embrace the medication’s expanding role in direct cardiovascular care, independent of its metabolic impact.